A stable prostacyclin analogue reduces high serum TNF-alpha levels in diabetic patients

Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association
K FujiwaraM Itoh

Abstract

To confirm whether a prostacyclin (prostaglandin I (2)) affects the increased TNF-alpha concentration in sera of diabetic patients, we measured serum TNF-alpha concentration and treated these patients with oral administration of the stable prostacyclin analogue (Beraprost). Twelve of 20 type II diabetic patients were investigated for follow up-study and 6 of those patients were for therapy with Beraprost for diabetic neuropathy. Serum TNF-alpha concentration was quantified by EASIA using monoclonal antibodies directed against distinct epitopes of TNF-alpha. In diabetic patients, serum TNF-alpha concentration was significantly increased compared with that of healthy subjects. The augmented TNF-alpha concentration in these patients was not decreased by diabetic control using antihyperglycemic agents for 8 weeks but was reduced with oral administration of a stable prostacyclin (prostaglandin I (2)) analogue for 5 weeks without any changes of blood glucose levels. Stable prostacyclin analogue administration for a short term period reduced increased TNF-alpha levels in diabetic patients, not through the improved hyperglycemic condition but another pathway, probably a cAMP system. These results imply that treatment with the prostacyc...Continue Reading

Citations

Jul 5, 2016·Annals of Vascular Diseases
Jan 5, 2006·Forschende Komplementärmedizin und klassische Naturheilkunde = Research in complementary and natural classical medicine·Steffi KoppraschJuergen Graessler
Jun 26, 2020·International Journal of Molecular Sciences·Daigoro HirohamaToshiro Fujita

❮ Previous
Next ❯

Related Concepts

Related Feeds